Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss.

Background: Nucleos(t)ide analogs (NAs) cessation in chronic hepatitis B (CHB) patients remains a matter of debate in clinical practice. Current guidelines recommend that patients with hepatitis B e antigen (HBeAg) seroconversion discontinue NAs after relatively long-term consolidation therapy. However, many patients fail to achieve HBeAg seroconversion after the long-term loss of HBeAg, even if hepatitis B surface antigen (HBsAg) loss occurs.

The Value of DNA Quantitative Cytology Test for the Screening of Endometrial Cancer.

Objective: To evaluate the accuracy, sensitivity, and specificity of DNA quantitative cytology test for the diagnosis of endometrial cancer or precancerous lesions and then discuss the value of DNA quantitative cytology as a screening tool for endometrial cancer.

Methods: The study enrolled 575 patients from September 2013 to January 2017 in Shanghai Minhang Central Hospital. Endometrial hysteroscopy plus dilation and curettage and DNA quantitative cytology tests were conducted as a method for the diagnosis of endometrial cancer.

Metabolic-induced cytotoxicity of diosbulbin B in CYP3A4-expressing cells.

As a candidate antitumor agent, diosbulbin B (DB) can induce serious liver toxicity and other adverse reactions. DB is mainly metabolized by CYP3A4 in vitro and in vivo, but the cytotoxicity and anti-tumor mechanisms of DB have yet to be clarified. This study aimed to determine whether the cytotoxicity and anti-tumor effects of DB are related to the metabolism-induced activation of CYP3A4 in various cell models, including CYP-free NIH3T3 cells, primary rat hepatocytes, HepG2 and L02 cells of high CYP3A4 expression and wild-type.

[Clinical characteristics and effect of secondary individualized therapy in chronic hepatitis B patients infected with the rtA181 mutation hepatitis B virus].

Objective: To investigate chronic hepatitis B (CHB) patients infected with the antiviral-resistant rtA181 mutation hepatitis B virus (HBV) who have been unresponsive to general therapy to determine the effects of individualized therapy.

Methods: Fifty-four patients with confirmed rtA181 mutation and who experienced virological breakthrough during nucleus(t)ide analogue (NUC) treatment were enrolled in this prospective cohort study. Their serum levels of HBV DNA, hepatitis B surface antigen (HBsAg), and alanine transaminase (ALT) were tested.

Systems toxicology used in nanotoxicology: mechanistic insights into the hepatotoxicity of nano-copper particles from toxicogenomics.

In some studies, nano-copper particles have been found to be acutely toxic to exposed mice, with the liver and kidney being the target tissues. However, the characteristics of subacute toxicity from repeated nano-copper exposure in rats and the molecular mechanism of its hepatotoxicity at the genomic level remain unclear. We investigated the mechanisms of nano-copper-induced hepatotoxicity, which were identified from hepatic gene expression profiles that were phenotypically anchored to conventional toxicological outcomes, and identified biomarkers of nanotoxicity caused by nano-copper.

Bis{μ-2,2'-[ethane-1,2-diylbis(nitrilo-methyl-idyne)]diphenolato}bis-[(thio-cyanato)manganese(III)].

The reported structure is a monoclinic polymorph of the title compound, [Mn(2)(C(16)H(14)N(2)O(2))(2)(NCS)(2)], which has been characterized previously in an ortho-rhom-bic form. Each Mn(III) atom is chelated by a tetra-dentate 2,2'-[ethane-1,2-diylbis(nitrilo-methyl-idyne)]diphenolate ligand and by the N atom of a thio-cyanate anion, in a square-pyramidal arrangement. The complexes form centrosymmetric dimers, with an Mn-O contact of 2.

Lignans from bark of Larix olgensis var. koreana.

Six new lignans (2-7) were isolated from the bark of Larix olgensis var. koreana, and their structures were determined on the basis of their spectroscopic data. Seven known lignans were also obtained and identified as (+)-lariciresinol 9'-p-coumarate (1), (+)-lariciresinol, (-)-secoisolariciresinol, (+)-isolariciresinol, vladinol D, sesquipinsapol B, and ehletianol C.